<SEC-DOCUMENT>0001193125-13-202841.txt : 20130507
<SEC-HEADER>0001193125-13-202841.hdr.sgml : 20130507
<ACCEPTANCE-DATETIME>20130507061418
ACCESSION NUMBER:		0001193125-13-202841
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130507
FILED AS OF DATE:		20130507
DATE AS OF CHANGE:		20130507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		13817880

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d533554d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Form 6-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>UNDER THE SECURITIES EXCHANGE ACT OF
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the month of May, 2013 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Novogen Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Translation of registrant&#146;s name into English) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1-7 Waterloo
Road, Macquarie Park, NSW, Australia </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive office) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form
20-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper
of a Form 6-K if submitted solely to provide an attached annual report to security holders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of
a Form 6-K submission or other Commission filing on EDGAR. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant by furnishing the
information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Novogen Limited</B> (Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Andrew Bursill</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Andrew Bursill</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Secretary</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date 7&nbsp;May 2013 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g533554tx_pg003.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7 May 2013 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ASX RELEASE </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Novogen Oncology Discovery Library and Indications Expand </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novogen today announces completion of screening of its second generation of <I>super-benzopyran</I>s in its ongoing drug discovery platform. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s current lead drug candidate, CS-6, is a product of the first generation of compounds. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The discovery program aims to use the Company&#146;s proprietary &#145;bend&#146; technology to both strengthen the Company&#146;s intellectual property
position as well as identifying new lead compounds. Using CS-6 as the starting point, the program constructs new compounds of differing shape and increasing complexity. The objective is to discover new lead candidates with potent activity against
various types of cancer stem cells and regular cancer cells. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laboratory screening now has identified melanoma and pancreatic cancer as being
highly sensitive to second-generation compounds, with two compounds showing particularly high potency. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Newly appointed Novogen Chief
Scientific Officer, Dr David Brown, said today, &#147;the identification of two new hit compounds against pancreatic cancer and melanoma nicely complements our pipeline of CS-6 with its key indications of glioblastoma and ovarian cancer.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Our task now is to decide which of these two new compounds we will fast-track through to the clinic in parallel with CS-6,&#148; he
added. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President of Novogen North America Inc , Dr Andrew Heaton, said today, &#147;today&#146;s results confirm our belief in the exciting
potential of our ability to &#145;bend&#146; small molecules to deliver specific activity against specific forms of cancer, and to meet our mission of developing a family of drugs providing comprehensive activity against both regular cancer cells
and their progenitor cells.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Novogen </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol &#145;NRT&#146;) and NASDAQ (symbol &#145;NVGN&#146;). The Company is based in
Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The Company&#146;s inaugural drug candidate is CS-6. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About CS-6 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells, cancer stem cells. CS-6 shows broad
anti-proliferative and cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being
developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Cancer Stem Cells
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancer stem cells (CSC) (or tumour-initiating cells) are believed to be a subpopulation of cells within many types of cancer that are
responsible for driving the growth and spread of the cancer. CSC typically are resistant to radiotherapy and chemotherapy and are thought to be responsible for cancer recurrence following therapy. Targeting CSC is a new direction in oncology drug
development as a means of preventing cancer recurrence. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Further information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Contact Dr Graham Kelly, Chief Executive Officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">M: (61)&nbsp;0459 200 095 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">E: <U>Graham.Kelly@novogen.com</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Please note that the Company currently is relocating offices and that the original phone numbers no longer are in use. New contact details will be
available shortly. </U></I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further information is available on the Company&#146;s web site, <U>www.novogen.com</U> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g533554tx_pg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g533554tx_pg003.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*P":`P$1``(1`0,1`?_$`,8```$$`P`#`0``````
M``````@`!@<)`0,*`@0%"P$``00#`0$```````````````0%!@<!`@@#"1``
M``4#`@(%"`4(!0T``````0(#!`41!@<`"!()(3%!$Q1188$B,A46%U(C,S88
MH<%"0S1%-SCP<;'Q1)'18I*BLL)C5#56.0H1``$"!`0"!P,'"P,%`0````$"
M`P`1!`4A,1(&00=187$B,A,4@:$(D;%"(S,T%?#!T>'Q4F)R0X,6@J(U8W,D
M9(0V_]H`#`,!``(1`Q$`/P#OXT00M$$+1!"T01@>H?ZAT00/%_9KMZPLVX1Q
M/-KMVC_.$5E!M9[E90B9WUSX^CK>N0T"@"AR$.X?VVN_<%*%3&\$(!Y_9EE3
ME.71BD<(:*J[T]%=6;94G2I],DDR\?Y</=!"$,(@'7U!TC3I_NUXCKSAV,\@
M9QLT#+'.,PM$$+1!"T00M$$+1!"T00M$$+1!"T00M$$+1!"T01I%2E`J7I#\
MO^76,1@?%&BEI2=*C(]/"/(#CPUZ!Z:>3\XZS)7&4;##!1';PC('`:=(!7HH
M/:-*T#IZ>C1V1E7=S(CR$0`*U#1!V1ZXJB83E`2=!1ZA$1'S>2NLZ23EA&%!
MQ"=:T]SJ)G\DHYPO_I$4ONS-O>UO<'C6:=6O>&#-S\3,P=U1XF+)6_+S5IW`
MG#/6WJBB9`92*3(L12J:R1C)&`Q3F*+]MII+E;Y3DB@\.$HH3GG45=#8*&_4
M4P[356HG&?#.4NB#)Y4G-,L?F#XS6C)TL;9NY''L2Q#*N/4%#$92"`&(S)D"
MR0<*'5<VI,NC`"B-3K1CH_<*B)1255\;[:';8Z7$`EJ9SZ(E'+?F31;UMX;.
ME-R;`U`8`B68!),_;G%O9#<12C6HB4HCZ0KU=FF5)U`*Z8M,$$3&4:Q.:H@'
M!T"(``CZW0%:]?;Y-;81J52)DH>'`<9PN,U.PHT#I[*CU=NL3$\CIC()TB8[
M\LL<_D,8(H-/6$M0&G0(4'TB(?V:V4`(QWQ]II0>B<\.W"-H"(^3S^;S=>L1
MOVQXG,)1"@EH("/3UCU4ITZR!.,=Z<@)CIZ/<80'&OK"4`I4`KT]?G'6"!+K
MC$U<1AT@X?-&1/3M#TC3\^M>_JD<HR"%>'],8XQ\I0]-?[1#6W:#*`S`F3+M
M&'SQ@5```&H=?52G_%T=>L#K]D8*DH'?.'3P$8XS``B(5IY`\W]?5K514G.4
MH,>D$'*49*I6H")0$.P?[^O0-8`"I:SE!K05%*3B,XVZVC:*<^:?OXS1LA6P
M`CAS'MJ9'D\M3UZQ\C"W%[].^.VM6-BI0&\"$*\;#XYPW<+]*I52EX`$"C00
M&,;FOR[*MDI;"TK(!F3AV2B_>1/*6Q<R%W9.XJURDI*-M"TN!*2-:YA(5J(D
MG4!C%@NVS<+8FZ+"F/,W8XD/&VO?<$WDRMS'*9]"2J("C.6W+@03%3E(&325
M;+$#K.GQ!4H@(O%!74UR0'V%&:1B.B<5-O;:=TV7?ZK;EW;(J&%XE/A4@]YM
M:#Q2M,NPF4#A8^[6_+JYCN:-G;NW[9;8^QG@VRLH0]S-QD_B]].7,M$)NH^3
M[QV>*"+03D#"GW:)5>(`J80#2-FX*%S50`$RXF)#7[)9I^6-OW\VX2Y6U;K!
M;(`T%L3!!S,QG/"-6^SF`6MLV965:,3:$WF3<%EM\6(Q%A:UU#$E[B=*.2L/
M>DNZ31<JQD$D\."8'*D=9=4!(D6A5#DWN]U]"V$4:0[6*4`$DRQ.$\.N'#EK
MRPK=^"INKSPH]GV\`U=4O^F#P0#@I1$Y=&&<"R;(?/&);1LC#A?9XK]4>1/@
MU&YKH+?IHT`.N,:G<2LF-NC.BB'=E2!P)3*B'3V"R^;NYPZRTVF7`*)RZY1,
MTVGX=:=\VI-1>U56J7KM(+1Z]'`=<LH'#<SGNU^:YRSMWF-XNR)['FYO`D0T
MOR\,&7$`N+EMB\<4RX7)W\.8Z#=Q*P\RWAY%@F<4TG"3@_<JE*)B">5[-O[#
MUT##QT5C9^L3^[.64\\8HWXG^2]QVEM9VG0H7"P5S8>HZID!3:QIU:5D3"5I
M$]0'#&.,S;3N(R7M9S7C_/N)95:-N^Q)=O(-D#+K(L+D@UCIEG[-N!%(0!U;
M]SQ8G:N4CU`O&50`[Q,ABWA<J-NNH2?$2(^6NV-PUNU+RQ5LK*/+<[Z1D0#D
M>J/T_MLVX*S-T&!L6Y^L!8XVID^SXVYF+-54#O(9VN049F`DS)B)4Y.WIE!=
MDX)V*H".J=K&54CZF%>,9<,(^B^V[[3;BLE/>Z:7I7F]6&,B,%#V'"!:PUO"
MO3-&\_=AB*(B;39;=]KD%;T+/9'64DR3[W+<FV&1G(4SQ1Z2"0@;<C6CDRYN
MZ%8#)>L8`ZXZQ>$KK7V2GZFG5)9ZY`Q=^XM@T^W]F66[NE2MQ7=2G$,R'V0,
MDG][4HD"4NR!*9\Q+=SO$R%=EK<MS"EBS6*+`F3V[<6Y#/4I)QEDS<ND!>\3
MLZ#BCHOWR14A!5,?KUE$#%5.FB4Y`,T*W'5W=]5/9V@4),M1)$Y9^^+$J.4.
MS.6EK9N'.*M?3N"N;#K5#2J!*&U8R=XH4!PRZ8]>Y.8%O6V57;;R7,/P98#S
M!MVS36WVNXG;M(34C!6C*O>+PXWA;LL*SU)`X$XP(!6ZIR%-W(+G+W>O=V]U
M]G+:+TVGRG%2"TDG'HEEA!0\I^7',JD?5REK74WUEOS/0UA'FNI$YEA7TCA@
MG$#W1=0-_6PA9Q[^7N&'3LL+=&[E+M,_2);Y+7"-++#<`R9C@W+%%C!\0*HF
M`@)>M74D#Z?(]2HI#`Q))^C*<XYQ%!<A6*MRF'57-+Y9#*4DN:]6@)4G@9YQ
M3/%\P+>UO)FK@<\NS;W8YL)6W,O(`FXG<7,R4!;MZOF*W<.EK*MB-52DUV:)
MP`>(_>J<(E[PJ1QX`BJ+Q=;QJ<LK:/3(<4G4HD:I9&.BZGE9R_Y=):9YN5]2
M;^XTEQ5!1@*6V%#5I<5]%4B,#+C*)EQ-DWFT6WF*QK/W#8%V[7IB6ZI@T7<&
M4,-WI,1KVQ61(]R\-/RD!/G6=/68G;`B5!-OQ*K*%+WA`-4%-,=P)=!K4-^5
M_"2<8C.Y;;R3JK0[7[+J[G37%`PIJE*3J!_BG+Y"3U2B1>97NURQM&Q)BVZ\
M-VS9%UWGDC-UE8D:1U_+RZ,"B:\$9(K1<[B(=,W*!BR#5$IE#B<A$CF$2FZ`
MTKO=;7426U4*`Y4+6!(F4@09F&;D[L:Q[\NU72[D?J*:W4MN=JBIA'F+^KE(
M2_=QQ,0>O?\`SQRIJ%)@+8H*M!*D)LJ7V4.]X1X.*A`-W8J4K^E3SZ\0YN@J
M`-.UY9(S7ACV8_KAX?MG()A@J1=+OZC2=&NG2$%4LB?FEQE$^<P#=3E;:!L^
M<9QMZV[-G<E1TSC:WY"!G%I5Q:B<I=TBTBYTC56-=L))5)H^6.5J85`X@`HF
MZQUZ7ZO=M5I55NI'G@@!()E/AC#5RCV19-_;_&VKI4KHK$MMQP/!(42E`"A@
M<!@<9]$.#E][T$-Y^$B7=*Q"-G99LN;?V+FO')#N"*V;?<8L8BQ6R#TYY$D%
M*MR]^T,M4X`"B9A$R9M>UEN;=SM_UQ"*U([Z1]$G*4^F$W-?EV_RXW*JAIW$
MU5C>2%TKZ9:7D'#A@%)/B`RSAM[BMW>0,1[X]F.V:W;<M63LW<8UR`XNV;E/
M>OQ##GM)J#AI[A,U=HQX=_TBKXA)6H!0*:2W&\)I;S14DB0],=D>VT>7M'?^
M7%]WDIQ:7+6ML2`!"BY/,G$2(EA%D'K^?J\H=7^?SZD<55.*+.:DBFYWB<I5
M!5,BJ+C<S-(K)*E*HFJDLWMQ%1)1,X"0Y%"&$!`0$!`=0O=3:7;A1-J$P5QT
M[R.<=I^7^]W`096QLS/#Q8C'`@Y'A#-QD97E;[]);!<FN9ALTWNW&^NC"KQ9
M0$(/$.<USIIR=A\:H`U81=P'631;EXB%!-1F`5[I8VL,J5MVZ+"U#\/=$YRD
M$D8@?ZC@#TF"YLL<X>62-Q,J4O>VW$);JQ.9>I$G4E<A(S1QSPG$E8>Z>>9N
MR!(QQ$NT'$Q:F#UA/XJV@,(UH(!Q:5LU*_\`+:AM:1-5,E8'4J7S0P;D82?A
M\LE4`0Z]>*I0QPT"8EIX$],1Y@.(;Y<YYN[N\+W2,^D=O.'+'MO%C61^L1@F
MMP1D$TD92*2,)BH+')+/1*):"49$XT`3:04J0_O1]ITS2RB8'293F.R);NM8
ML'PSV2BM94A-WN;RZHH)'F!M,T-J(STG'KEE%^9D4P`]1'B*7U1,)J!2M`Z]
M3H.*&(RCD\,XS0I8Z@M4_:)R]T4"Y4AHW$G/8V[S5H-6J(;FMO=[1&6X)D``
MA,>Y(Z?9LYZ<9IEX'(.B6PP#C4*/>"S$1,(B:L#J4(HM[,*HTD+J$:G#/KCK
M"SA6Z/A4O%'=3J59;JVZC4<T.I"7&VP9DC.0!P$<Q'.$Y>%P[%MQTN^MN(<?
MAUS%,S%V8=G$D5#L8)P^64DIS%<HX`#))2]K+N3F8@(@9U%BD8H"9-6G16V[
MLFJ;].L]_+\NJ/C!S:V&[M.^*N=(RI5JJ9Z!+PSZ>`(XQ;_R"=ZS/%.P_>A"
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MRAC&&@`6M``-3.S4S%);&#2)3WD`DRQF1,^^.>>:5]N-XY@W6XW0K75N5KFH
MK!4$)2HA(0#X4R&`&0A[[O\`&%I9;VRYXL2]&:+VWIS%%Z)NB+@!A9N8V">2
MT7+-14XB(R$/)LDG+94``R:J8"`Z+O2-5-O?;?`4D-E22<TJ`./S?)"3EW<Z
MRR[[M=?;U%NI->P$K1,*TJ6$D:ADD@G`@B.;>X<U9`#_`.=&V#>\)!!S(7.R
MP>[G%'"PJH8_;9,>M"HF6*(K"P/#,",!+4`%&J?LC34`=N%14;`%4X?K?!J&
M$TZY8QV/_C%LIOB^?;<;1JIT+J]*2)*=2S,$G*>J1(EG'37MKQI9^*L"XCQS
M8L>VC[3M7'-GQL0DT(5-!<IH1HY=2(B0I>\=2KQ4[E<XA51543CZPCJPK=2L
MTE"RPS)+`;3*6$R1B3VX1Q1O2\7'<&Z[C>KLM;EUJ*MU:U%2IXJ4`F<\DA,@
M,)0X+ZS)BO&<[85L9`OBW;3N#*,X>UL=Q,])D9/;UN,G=&&$@6YO6?R)06(/
M`7IH8!TK=<:86&U*[RQA/J$X;*.R7:XLU#]`PX\U2H"W"%8!)!,\9\1**D>>
MK).XK`VV:9C8=U/OXO>+AV7CX!B=--_.OXXLR[9P[)1<012=RK@A6Z9C^H4Z
M@"?H`=1#=SKJ&:9UM!<47DX=0!GEVQT-\,E'1UVY;M0W"I]+3+L50A3FDJ"1
MA.8'#B8GFP-]6Z6\K]LRT[FY9FXG',%<5QQT/-WY<-WX_=05I1[Y<$G5PR;9
MBN=XLRBDA%10J/$<2AT:6,W:H6^EM=*Z@"1GB,L<\HBE^Y9[&MM!45E)NVW5
M[C314AMMI>I1P[H)40"?;QB-.>N80Y>EX``@8HY5PT''T"%/C5F82CP]8`(4
MZ?+I/N]U*;.2XF:55"!+CWL?=#O\-"`KF:"4H#:+75J`(FE4FI24#GT_)$&;
ME8Z5Y<NZ'&?,!LMDZ';KG>)LG&.\ZVHI$3(PLPY9-4+5S$5D3ZGQ"2M/$JT`
M3*IJE$>-Z(Z\*JF59+FB[LF=&4)2\D83)P"^Q.9'&)-L]QOF]M*IY6U6E6\+
M<NHJK6X9=]/>+K&..(3W!/#"'AO"F&$_S7.4_-Q#QK(PTM`9@DXB58K%<,Y*
M.D80CIF_:+)U(JU=-52'(8!$#%,`AT:+@\V]?[8\)*UA6GLQQ]F<>/+5+M-R
M'WQ;])"VW&"Z")%)22DID<?%.+X?1^C_`$#4VCE[]$46\T@5#[S>4<9-)02E
MW/R@E$I#&`.)*V1`#F+4I*`/6(TU$-QH<5=J/0#)#@!/#&.D.3M=2TG+K?--
M4N(0\Y;$(2"<5>+P=)^2#^WS;3K:WD[>+VQ%,JEB[A<$3N+'%V`!@?6;D."`
MSJV9MNNB)5TFX/`[ET4I@$[54X=8!1[O-M:NE*]2NX$MB1Z%`S2>R8$^J*JY
M9[YJMB;IIKRVG5;UMZ*IH^%UE7=<"Q@#W"2)SQ$4=<I')V6LG<R?/3G/,2O$
MYJL7:Y:N'\FHO!,+N1N7&%T0ELJ3SDHII\*\TU;(K*"`F(N<XK$'@4"D&VL_
M656YJI5P0?5-4R6P?HD)PP.$_DCI[X@[#M.P<G+0]L^L:J;-57E]Y@),RA+R
M"LH(S`23(<.$%-OFQQFK9_O+MGF7X%L68RE9DS:C3'6Z?%]LIJN;D=6JT3;L
MFUYQ,>V(LH]!NS9-#&.5,YFKI@F90.Y65.FZW:CJ+9=VKZRD^G""'^F4L2`,
MY#VQ`>6][L>_-@/<G-RU;=*ZTXJIM]0LR2E\CO(6K,!0P``,^J)R4YW/+V)8
M"EV_-^1<7"HRJEB9M9=U'RH:4[KC"$^'%(@K4'G'ZG>BZ\+Q?K=+G-Z[:]-W
M*B:R,`$+GU8:>F(RCX;>:=1</34]"E-I!^_><UY9$\58JU2ECX9]40CL%Q9G
M#<_NZOKF8[B;'E<50SJTE\;;7\77"DJC<$-8SDIT5KIDFBQ4UFI'<:LN"9E$
MT3NW;]RJ4A42(\2*SLUE9<Q>*U/ELI:T@+P5/LQ$O;$EYI;BVSLS8E-R9V>\
MFKN"*@5%RJ4R*774^%#9G@@=8BVO<IMHQ-NMP]=>#<TVLUNNP[Q9';.T5*(R
M<))I$$(FY[8DRD%Q#7/!./KF;I(0,0P"4P'3,<AI[1U#M$\'6#*.3;[8Z*_V
M]ZW7!(<:>!$SFB?%/6.$<1-E;`\Y[9^85+\MQ\\=S^-]TLA8+]Q?**1V"5_;
M=\=7^&07LR9JBKW#>6C6\2O'S25#%0=``%HFNF(K]Z5GXU8:5M!^N#WUD\I3
MR_;#/\+=JI^4O,7<577S#5/:5"A6K$N..*4`O^9(.$LH[<<_X%M#.VW?(NWB
M72&*M2_,?N[&159)`)H!+P1&T%(,$B@!3JP;QLV62('0;N0+U#J-5UO34VM=
M"WITRD/G$6MMW==RVWNFFW?3]^X4]:'C/Z2BH%6K+`B<^V*2]FF_1UL)@XG9
M1S%8JX<3OL0^)M_%&=5[>GI;&>0K`:N'`6\12=BF;X"+LFI@3;KE`Y!;%(DX
M*@LF;CC%INCMK3^&7`*2&Y]Z7=(.(D>KLCH;F!RO<YE5#G,;E2\FM:KU>95T
MFMI"Z99\0TK6,"9D2AQ;PN9&AN^MF5V>\M^,GLY9'S"P5M&\,K0\'-1.-L96
M3+E,SN:1<73+,621'KF+442%P8I4&R!CG3%984T]>UTO"[B4T-GFI*YATY#2
M>`SF?DCPV%RA9V%5IWYS8J$6RR4$GVJ?6AQZI6D@MI2E"E`)F)&:@>J4&^KR
M\;+?<N=OL'7DD@CFF-6T"E=X-C"*>1V[HMSDODC;B*J#<;UJY%+BXS-A$G%4
M:Z6?@*%;<58VP/+T2$^G5JF9`_-.*\'..Y'G&KFJVA)*JQ2RP#W?(/="53D1
MW,QEJZ1`([5^9=);++?A=HO,GM6[\27GBMDSM"S<V%M^9N/&N0[*ADA90$DI
M-PS9XJ9VA&()HE<-TUR+IE)WQ4%P4(#>S>::SJ])>EEI"0`V=*E!02,<@<L,
MXL?>?**GYBU3V_.5#K-9;:TEUVF\Q#;K+JP2I*4K4)IU$RQX&&1NWWF;<=XV
M\+EHPFV?(),PO,<;F6UQWD:V+<NL&4-#OV\2D@^<R#^%9MP1`4#]X8!^J`M3
MB4!"OE4W^UW2[4?X>XIT(<)6`E0DDIE,Z@`<9<84;-Y=;DV#L/<M=O1MNA-5
M0);8"W&U+6L*,TA*%*(,C.9PE!*\\V:80.#-LUQ2BQV<-;N\7#]PS+DK=9R5
MG$0X2\G)/.Y:I+.%4VC)L<X@F!C"!:`'2&E6\E-4U/3+>>++*7T]]*2K/5A(
M`G'\T1CX;V7ZF_WJCI6RY5+M%0V.^&YJ64@'45`%/>$QQ]D3>/.<Y<0IBH?<
M")`2!0X".-,K'X4R@<R@GX;+.(E$I>F@#Z=*T[LL9`ID5)=<6)`>6H$GM*0.
MO.(RYR$YIE;B$4*'&^.EUD8#$]XN2,@.J<1#SJ;EA[WY:#V[+9<>\K=NN^L#
MW'"/DF[I$[^'FKKBI"-=E:N42.T?%-7)#\"A"G)Q4,`#4-:[L:35V?6R"KZU
M"Q+H21[X?_A]IW;;S4=9NZA3J8HJU.*DZ4E+9$E$$B1.&$YQ:->.*[)S1A&2
MQ9D6'1GK)OS'C:V[BBG12G[V.?PK=%19N)RJ`W?,C<*[=4`XDETRG#I`-/CS
M+-93*IJ@?5NMX]A&/MQ^6*6MU_N^VMSM[@LCGD76GJ"MM8,C-*YJ3_(H8=>1
M$<JF#87,N%^:-L=V>9H<O9K\+MW95@<17L_`P*WEA2_+:EI^PUTS*U%=.()&
MN&M0,843`9O0/#EXJQ917,[NI*-])+-/J"%#+0<I]<=V7NX[1W#R*W+O/;9:
MIZZZ)IO5L"0D^V).:0)S"U8\)YQV04'_`&:>G5M81\^8BZZ:>^+/K\!_]W4^
M]?%[XI4*_"7#^^*^FM*:2UOWA'V<]0SS]G7T0^4>KTE3+U<O+'V4M']Z>.GL
MA\J4\*;V/8'V^+AI4]>\[*4Z^WTZ5N^)667Y3B-U<OKIZ9>2,YR]V.GIEC$"
MV=3YV7W_``'_`&!'[J<7SJ_=U/C^O[NI[/G[KMTS-2]:O[&>GZ$]?MX1+Z_5
M_C5%_P`GITG[73Z/^Q]+7T^WC$\J^P/V/V"GEXNO_<^EYM/>/E&?^^4LN,N'
MYHA]-IT)_P"Z/!/5GQ_/PBOUK7YZG_\`7S7WLM]GP_/GK-[5>CWK]/TZ8$ZO
M4&?H9892]W&<709_@PG_`)7+3U>F]DL8L"3ZC?8>R3V:4IP![5.SR=M-/-3+
MRC/3_JG+VRBG#XW)92QGX\OZL\9?R\(^P'4'L^S^;M_T-9&0CT'A]D##=W\Q
M^+*_A^I\"Y$^]]/Q'_M437Y2\/K?+_\`\C[./N*:RG[LO.6HY^'.&ZKEYJ-6
MB<AXI^9X_P"'#1T3QE*<$@7V2=?5VTX>OS]/%7J\^M:;(YPN5/U0EJR.66?T
MOU0.^XFOP$M3Y`_M@5_$3P_`/7TUXO\`$^2G3Q::+[I\D:O32_ZFKIZL8E.S
M]/FKT_B?'[AJZ?ZNKAT2CY>V;[EN?Y;Z>*/_`"T_<[J_Q=/6\1Y?/I-8M'G]
MSTF7]+7+_=QA3O2>IG5^,S_]WP_VY8:>B?'."31_64[G]7[%?)^E7\GIU*?I
M&((G[=4]&N:<O'E].7=ET2X9P/FX6GP*Y_@!3O"<7XBN+X%ZS_:_I>*^CP::
M*Z>L2]+.9\?LZ<.V)KM/_DC+\8U=W[AEQZ>[/L]L,3;%3PKKA_!]3@4I^&;C
MX:T_>'>>OP4ZZ]'ITG;GYG>])E]"4_=#]O#5Y2I_Y!P^^2TY]7YH(F^Z^ZV5
M/E_^U%^_=/=/V)Z^$X^CQ?Y>[XJ:6U'V0^RS_J9<<NOHB'6B?JG?OTL/N\I\
M/%Q^3"(@6XN`:?A?[?:[KB[?:XNSZ7FKINJI:1J]#*8\4^GAIQ[(F2<Q_P#I
M,QX<OV=,N$XDZZ_N6R_AY7AB:_$OW*]M*O@Z^K3_`*.G17AIIQ>EZ9,O+EAT
MZ/TR_5$)H/\`GG-'KM6AS[#[7,_::L)?O\>B)#9T\,C['V0=7'W=.Y3^S[>X
M^CV\.E+OB1EE[/V0AJOO+73I5V_MZ8@6[J?/+'?\":^[7%/BKC^<_P!J_P#N
M'3U/=E/;K_S>W2*IEZQ$_(G+KU^R6$HD=GU?XC5Z?Q/R_,$_)T^C_P#HU=_5
1T:>J"5_UO9\W].+2^(S'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
